UBS Reiterates "a 120.00" Price Target for Merck Group
The brokerage presently has a "buy" rating on the healthcare company's stock. UBS's price target suggests a potential upside of 49.07% from the company's previous close.
from Biotech News
The brokerage presently has a "buy" rating on the healthcare company's stock. UBS's price target suggests a potential upside of 49.07% from the company's previous close.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments